Skip to main content
Premium Trial:

Request an Annual Quote

Pushed a Bit Later

Novavax has pushed back both its timeline for filing for authorization for its SARS-CoV-2 vaccine and its release of a report on its vaccine trial, Bloomberg reports.

Earlier this year, Novavax reported that its vaccine had nearly a 90 percent efficacy rate in preventing COVID-19 based on data from an initial UK trial. It further said that its vaccine was highly effective against the original viral stain and the B.1.1.7 variant, but had a lower efficacy rate against the B.1.351 variant.

In March, Novavax CEO Stanley Erck told CNBC that the company was aiming for May to receive Emergency Use Authorization from the US Food and Drug Administration. But as the Hill now writes, Novavax does not plan to apply for authorization in the US, UK, and Europe until the third quarter of the year. At the same time, it now plans to release its trial report at the end of the month, later than expected, the Washington Post adds.

"We know that we're delayed from where we thought we'd be at this point," Erck tells Reuters. "Now we're giving guidance that nearly all of the major challenges have been overcome and we can clearly see the light at the end of the tunnel."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.